Premium
Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice
Author(s) -
Bijl Nora,
Sokolović Milka,
Vrins Carlos,
Langeveld Mirjam,
Moerland Perry D.,
Ottenhoff Roelof,
van Roomen Cindy P. A. A.,
Claessen Nike,
Boot Rolf G.,
Aten Jan,
Groen Albert K.,
Aerts Johannes M. F. G.,
van Eijk Marco
Publication year - 2009
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.23175
Subject(s) - endocrinology , insulin resistance , medicine , steatosis , fatty liver , nonalcoholic fatty liver disease , type 2 diabetes , insulin , biology , glucose homeostasis , insulin receptor , hyperinsulinemia , diabetes mellitus , disease
Nonalcoholic fatty liver disease (NAFLD) is associated with obesity, insulin resistance, and type 2 diabetes. The hyperinsulinemia that occurs as a consequence of insulin resistance is thought to be an important contributor to the development of fatty liver. We have shown that the iminosugar N‐(5'‐adamantane‐1'‐yl‐methoxy)‐pentyl‐1‐deoxynojirimycin (AMP‐DNM), an inhibitor of the enzyme glucosylceramide synthase, is a potent enhancer of insulin signaling in rodent models for insulin resistance and type 2 diabetes. The present study was designed to assess the impact of AMP‐DNM on insulin levels, liver triglyceride synthesis, and gene expression profile. Treatment of ob/ob mice with AMP‐DNM restored insulin signaling in the liver, corrected blood glucose values to levels found in lean mice, and decreased insulin concentration. The expression of sterol regulatory element‐binding protein 1c target genes involved in fatty acid synthesis normalized. AMP‐DNM treatment significantly reduced liver to body weight ratio and reversed hepatic steatosis, comprising fat as well as inflammatory markers. In addition, AMP‐DNM treatment corrected to a large extent the gene expression profile of ob/ob mice livers toward the profile of lean mice. Conclusion: Pharmacological lowering of glycosphingolipids with the iminosugar AMP‐DNM is a promising approach to restore insulin signaling and improve glucose homeostasis as well as hepatic steatosis. (H EPATOLOGY 2009.)